AXGN Stock: Price, Forecast, Financials & AI Analysis

High

Open

VWAP

Vol

Mkt Cap

Low

Amount

EV/EBITDA(TTM)

Total Shares

EV/OCF(TTM)

P/S(TTM)

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2025Q4

FY2026Q1

FY2026Q2

58.00M

+17.39%

-0.020

-300%

57.24M

+17.88%

-0.024

-69.64%

64.72M

+14.23%

0.036

+257.1%

Estimates Revision

The market is revising Upward the revenue expectations for Axogen, Inc. (AXGN) for FY2025, with the revenue forecasts being adjusted by 1.68% over the past three months. During the same period, the stock price has changed by 94.46%.

Revenue Estimates for FY2025

Revise Upward

+1.68%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-19.04%

In Past 3 Month

Stock Price

Go Up

+94.46%

In Past 3 Month

5 Analyst Rating

Wall Street analysts forecast AXGN stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for AXGN is 29.20 USD with a low forecast of 26.00 USD and a high forecast of 34.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

5 Buy

0 Hold

0 Sell

Strong Buy

Current: 0.000

Low

26.00

Averages

29.20

High

34.00

Current: 0.000

Low

26.00

Averages

29.20

High

34.00

H.C. Wainwright

Buy

maintain

$26 -> $39

2025-12-05

Reason

H.C. Wainwright

Price Target

$26 -> $39

2025-12-05

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on AxoGen to $39 from $26 and keeps a Buy rating on the shares after the company announced that the FDA had approved the Biologics License Application for its Avance acellular nerve scaffold. The approval further strengthens Avance's market positioning and should facilitate further market penetration of Avance in the coming years, the analyst tells investors.

Canaccord

Buy

maintain

$27 -> $37

2025-12-05

Reason

Canaccord

Price Target

$27 -> $37

2025-12-05

maintain

Buy

Reason

Canaccord raised the firm's price target on AxoGen to $37 from $27 and keeps a Buy rating on the shares. The firm noted the company announced FDA approval of the Biologics License Application (BLA) for Avance, formally transitioning the product from tissue-regulated status to a fully licensed biologic. This approval covers adult and pediatric patients with sensory, mixed, and motor peripheral nerve discontinuities. Canaccord sees the approval as a key catalyst for continued increases in commercial covered lives as well as societal and surgeon adoption.

Jefferies

Buy

maintain

$29 -> $36

2025-12-04

Reason

Jefferies

Price Target

$29 -> $36

2025-12-04

maintain

Buy

Reason

Jefferies raised the firm's price target on AxoGen to $36 from $29 and keeps a Buy rating on the shares after the FDA approved the biologics license application for Avance. The firm expects approval with a broad label will support continued commercial coverage wins and surgeon adoption as well as enhance the competitive moat, the analyst tells investors. The firm sees a "favorable setup" in 2026 with upside risk to Street estimates on continued commercial coverage wins, a sales rep productivity ramp and a reimbursement catalyst, the analyst added.

Lake Street

Frank Takkinen

Buy

maintain

$30 -> $40

2025-12-04

Reason

Lake Street

Frank Takkinen

Price Target

$30 -> $40

2025-12-04

maintain

Buy

Reason

Lake Street analyst Frank Takkinen raised the firm's price target on AxoGen to $40 from $30 and keeps a Buy rating on the shares, calling the approval of Avance with an unconstrained label supportive of use in all Axogen's present nerve repair cases a "best-case-scenario outcome." The firm thinks this should accelerate growth and "support a high-multiple takeout given the 15-20% growth profile," the analyst tells investors.

H.C. Wainwright

Buy

maintain

$25 -> $26

2025-10-30

Reason

H.C. Wainwright

Price Target

$25 -> $26

2025-10-30

maintain

Buy

Reason

H.C. Wainwright raised the firm's price target on AxoGen to $26 from $25 and keeps a Buy rating on the shares. The company reported a Q3 beat and upped its 2025 outlook, the analyst tells investors in a research note. The firm believes AxoGen's execution of its market development strategy should drive revenue growth in the coming quarters.

Citizens JMP

Outperform

maintain

$26 -> $34

2025-10-30

Reason

Citizens JMP

Price Target

$26 -> $34

2025-10-30

maintain

Outperform

Reason

Citizens JMP raised the firm's price target on AxoGen to $34 from $26 and keeps an Outperform rating on the shares. Sales of $60.1M reflected another all-time quarterly record in dollars and represented the second-best top-line growth performance in four years, the analyst tells investors in a research note. AxoGen has truly differentiated products for nerve protection and repair, and a biologics license application could help make Avance the standard-of-care solution in peripheral nerve repair over time, Citizens argues.

Valuation Metrics

The current forward P/E ratio for AxoGen Inc (AXGN.O) is 620.00, compared to its 5-year average forward P/E of -6.73. For a more detailed relative valuation and DCF analysis to assess AxoGen Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-6.73

Current PE

620.00

Overvalued PE

225.28

Undervalued PE

-238.75

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

23.15

Current EV/EBITDA

43.75

Overvalued EV/EBITDA

128.14

Undervalued EV/EBITDA

-81.84

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

5Y Average PS

3.16

Current PS

5.78

Overvalued PS

4.56

Undervalued PS

1.77

Financials

Annual

Quarterly

N/A

Total Revenue

N/A

Operating Profit

N/A

Net Income after Tax

N/A

EPS - Diluted

N/A

Free Cash Flow

N/A

Gross Profit Margin - %

N/A

FCF Margin - %

N/A

Net Margin - %

Trading Trends

Insider

Insiders areSelling! The selling amount has increased 565.21% over the last month.

Sold

Bought

Hedge Fund

Hedge Funds areSelling! The selling amount has increased 2920% over the last quarter.

Sold

Bought

Congress Trading

Congress are Neutral. There are no significant trading trends over the last month.

Sold

Bought

Insider

Insiders areSelling! The selling amount has increased 565.21% over the last month.

Sold

Bought

AXGN News & Events

Events Timeline

No data

News

1.0

2025-12-17Globenewswire

Axogen to Present at J.P. Morgan 2026 Healthcare Conference

4.5

2025-12-08NASDAQ.COM

ETFs on the Move This Monday: REMX, IHI

9.0

2025-12-04Benzinga

Axogen Reaches New 52-Week Peak Following FDA Approval of Innovative Nerve Repair Therapy

People Also Watch

Frequently Asked Questions

What is AxoGen Inc (AXGN) stock price today?

The current price of AXGN is 33.37 USD — it has increased 1.27 % in the last trading day.

What is AxoGen Inc (AXGN)'s business?

Axogen, Inc. is focused on the science, development, and commercialization of technologies for peripheral nerve regeneration and repair. It offers repair solutions for surgeons and healthcare providers. Its portfolio of products includes Avance Nerve Graft, Axoguard Nerve Connector, Axoguard Nerve Protector, Axoguard HA+ Nerve Protector, Axoguard Nerve Cap, and Avive+ Soft Tissue Matrix. Avance Nerve Graft is a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves. The Axoguard Nerve Connector is a porcine (pig) submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves. Axoguard Nerve Protector is a porcine submucosa ECM product used to wrap and protect damaged peripheral nerves and reinforce the nerve reconstruction while preventing soft tissue attachments. Axoguard HA+ Nerve Protector consists of a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating.

What is the price predicton of AXGN Stock?

What is AxoGen Inc (AXGN)'s revenue for the last quarter?

AxoGen Inc revenue for the last quarter amounts to 60.08M USD, increased 23.51 % YoY.

What is AxoGen Inc (AXGN)'s earnings per share (EPS) for the last quarter?

AxoGen Inc. EPS for the last quarter amounts to 0.01 USD, decreased -125.00 % YoY.

What changes have occurred in the market's expectations for AxoGen Inc (AXGN)'s fundamentals?

How many employees does AxoGen Inc (AXGN). have?

AxoGen Inc (AXGN) has 451 emplpoyees as of January 09 2026.

What is AxoGen Inc (AXGN) market cap?

Today AXGN has the market capitalization of 1.54B USD.